vs

Side-by-side financial comparison of Connect Biopharma Holdings Ltd (CNTB) and Recon Technology, Ltd (RCON). Click either name above to swap in a different company.

Connect Biopharma Holdings Ltd is the larger business by last-quarter revenue ($24.1M vs $12.2M, roughly 2.0× Recon Technology, Ltd). Connect Biopharma Holdings Ltd runs the higher net margin — 61.6% vs -6.8%, a 68.4% gap on every dollar of revenue.

Connect Biopharma Holdings Ltd is a clinical-stage global biopharmaceutical company dedicated to developing innovative targeted therapies for inflammatory, immunological and autoimmune diseases. Its core pipeline includes candidate treatments for asthma, atopic dermatitis and other conditions with high unmet medical needs, with main operations across the U.S., China and key global markets to deliver effective therapeutic solutions to patients.

Recon Instruments Inc. was a Canadian technology company that produced smartglasses and wearable displays marketed by the company as "heads-up displays" for sports. Recon's products delivered live activity metrics, GPS maps, and notifications directly to the user's eye. Recon's first heads-up display offering was released commercially in October 2010, roughly a year and a half before Google introduced Google Glass.

CNTB vs RCON — Head-to-Head

Bigger by revenue
CNTB
CNTB
2.0× larger
CNTB
$24.1M
$12.2M
RCON
Higher net margin
CNTB
CNTB
68.4% more per $
CNTB
61.6%
-6.8%
RCON

Income Statement — Q2 FY2024 vs Q2 FY2026

Metric
CNTB
CNTB
RCON
RCON
Revenue
$24.1M
$12.2M
Net Profit
$14.8M
$-832.7K
Gross Margin
33.5%
Operating Margin
56.6%
-14.6%
Net Margin
61.6%
-6.8%
Revenue YoY
111.0%
Net Profit YoY
148.7%
70.5%
EPS (diluted)
$0.27
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CNTB
CNTB
RCON
RCON
Q4 25
$12.2M
Q4 24
$5.8M
Q2 24
$24.1M
Q4 23
$6.4M
Q2 23
$0
Net Profit
CNTB
CNTB
RCON
RCON
Q4 25
$-832.7K
Q4 24
$-2.8M
Q2 24
$14.8M
Q4 23
$-3.2M
Q2 23
$-30.5M
Gross Margin
CNTB
CNTB
RCON
RCON
Q4 25
33.5%
Q4 24
31.7%
Q2 24
Q4 23
26.7%
Q2 23
Operating Margin
CNTB
CNTB
RCON
RCON
Q4 25
-14.6%
Q4 24
-63.9%
Q2 24
56.6%
Q4 23
-50.4%
Q2 23
Net Margin
CNTB
CNTB
RCON
RCON
Q4 25
-6.8%
Q4 24
-48.9%
Q2 24
61.6%
Q4 23
-49.8%
Q2 23
EPS (diluted)
CNTB
CNTB
RCON
RCON
Q4 25
$-0.09
Q4 24
$-0.31
Q2 24
$0.27
Q4 23
$-1.16
Q2 23
$-0.55

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CNTB
CNTB
RCON
RCON
Cash + ST InvestmentsLiquidity on hand
$110.2M
$10.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$110.9M
$66.4M
Total Assets
$120.6M
$77.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CNTB
CNTB
RCON
RCON
Q4 25
$10.7M
Q4 24
$19.9M
Q2 24
$110.2M
Q4 23
$36.0M
Q2 23
$81.6M
Stockholders' Equity
CNTB
CNTB
RCON
RCON
Q4 25
$66.4M
Q4 24
$66.9M
Q2 24
$110.9M
Q4 23
$60.0M
Q2 23
$128.7M
Total Assets
CNTB
CNTB
RCON
RCON
Q4 25
$77.6M
Q4 24
$74.2M
Q2 24
$120.6M
Q4 23
$68.1M
Q2 23
$144.1M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CNTB
CNTB
RCON
RCON
Operating Cash FlowLast quarter
$-8.0M
$-1.9M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
-0.54×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CNTB
CNTB
RCON
RCON
Q4 25
$-1.9M
Q4 24
$-1.7M
Q2 24
$-8.0M
Q4 23
$-931.0K
Q2 23
$-31.2M
Cash Conversion
CNTB
CNTB
RCON
RCON
Q4 25
Q4 24
Q2 24
-0.54×
Q4 23
Q2 23

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons